On September 1, 2010, Allergan announced that it reached a resolution with the United States Department of Justice (DOJ) regarding the DOJ’s criminal and civil investigation into Allergan’s past U.S. sales and marketing practices relating to certain therapeutic uses of BOTOX® (onabotulinumtoxinA). … Continue Reading